Skip to main content
Clinical Trials/ACTRN12612000804886
ACTRN12612000804886
Completed
Phase 2

A double blind, placebo controlled, randomised cross over trial to evaluate a novel and cost effective food supplement, butyrylated starch, on polyposis in familial adenomatous polyposis (FAP) patients.

Royal Melbourne Hospital0 sites49 target enrollmentAugust 1, 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Familial Adenomatous Polyposis
Sponsor
Royal Melbourne Hospital
Enrollment
49
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 1, 2012
End Date
May 7, 2018
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Medically diagnosed FAP with either an intact colon, or after colectomy with a residual ileorectal anastomosis (IRA) or ileal pouch
  • 2\. History of polyp detection at surveillance sigmoidoscopies or colonoscopies
  • 3\. Generally in good health
  • 4\. Available for the duration of the study

Exclusion Criteria

  • 1\.Intolerant to high fibre products
  • 2\.Reported lactating, pregnant or wish to become pregnant during the study. If a participant becomes pregnant during the trial they will be withdrawn
  • 3\.Reported use of nonsteroidal anti\-inflammatory drugs, aspirin or probiotics
  • 4\.Use of other medication or supplement that in the opinion of the gastroenterologist may interfere with polyp development or bowel or microbiota function for 2 months prior to and during the clinical intervention. Use of anti\-diarrhoeal medication(s) is allowed as required
  • 5\.Use of antibiotics for 2 months prior to the commencement of the trial
  • 6\.Use of other experimental chemopreventative agents, including EPA, tumeric and curcumin for 6 months prior to and during the trial
  • 7\.Colonic or rectal surgery likely within 18 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials